Strides Pharma Science Q3 PAT Jumps Over 2-Fold to Rs 208.12 Cr on Strong Sales, Property Sale

• Strides Pharma Science reported a consolidated net profit of Rs 208.12 crore in Q3 FY26, more than double the Rs 90.04 crore in the same period last fiscal.
• Consolidated revenue from operations increased to Rs 1,194.65 crore in Q3 FY26 from Rs 1,153.67 crore in the year-ago period.
• The significant profit rise was attributed to robust sales growth and a one-time income from the sale of an investment property.
• The company recorded a profit of Rs 102.14 crore as other income from the sale of land and building for Rs 112.87 crore.
• MD & Group CEO Badree Komandur highlighted strong performance in 'other regulated markets and growth markets' as key drivers.

Why It Matters: Strides Pharma Science saw its Q3 net profit more than double, boosted by strong sales and a property sale gain.